Evidence of comparative efficacy should have a formal role in European drug approvals
Sorenson, C., Naci, H.
, Cylus, J. & Mossialos, E.
(2011).
Evidence of comparative efficacy should have a formal role in European drug approvals.
British Medical Journal,
343(7822), d4849-d4849.
https://doi.org/10.1136/bmj.d4849
, Cylus, J. & Mossialos, E.
(2011).
Evidence of comparative efficacy should have a formal role in European drug approvals.
British Medical Journal,
343(7822), d4849-d4849.
https://doi.org/10.1136/bmj.d4849
Despite methodological concerns, comparative efficacy evidence should be required at the time of drug approval, says Corinna Sorenson and colleagues, to allow patients, clinicians, and other healthcare decision makers to determine whether a new drug is superior, equivalent, or inferior to its existing alternatives.